-+ 0.00%
-+ 0.00%
-+ 0.00%

EU Clears AstraZeneca's Generalized Myasthenia Gravis Add-on Therapy

MT Newswires·11/16/2026 02:14:47
Listen to the news
02:14 AM EST, 11/16/2026 (MT Newswires) -- The European Union approved AstraZeneca's (AZN.L, AZN.ST) Klygefa, or gefurulimab, as an add-on to standard therapy to treat adult generalized myasthenia gravis patients who are anti-acetylcholine receptor antibody-positive. The approval, which follows a positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency, was backed by the results of the Prevail phase 3 study, the drugmaker said Monday. The trial met its primary endpoint of showing improvement from baseline in myasthenia gravis activities of daily living total score at week 26, compared with placebo. A clinically meaningful improvement was observed as early as week one, and was sustained through week 26. The drug is already approved in the US, Japan, and other countries for certain adults with generalized myasthenia gravis, while regulatory submissions in China and additional countries are under review.